Mechanisms of Action of Interleukin-2 Superkines

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1148051

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Immunotherapy is emerging as one of the largest breakthroughs in cancer therapy in the last 30 years, due to the recent approval of the antibody therapeutics Ipilimumab (anti-CTLA4) and Pembrolizumab (anti-PD-1). This has greatly increased interest in other immune activating modalities, either for monotherapy, or in combination with antibody therapy. Here we propose to decipher molecular mechanisms that underpin the biological function of a new class of immune activating drugs (IL-2 superkines).

Funded Activity Details

Start Date: 01-01-2018

End Date: 01-01-2020

Funding Scheme: Project Grants

Funding Amount: $735,743.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Cellular Immunology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

T cell immunotherapy | antibody engineering | cytokine biology | interleukins (IL) | targeted therapy

Related Links

ACN 633 798 857